Skip to content Skip to footer
Subscribe Now
Pharma Tech Conclave 2023
EVENTS

Pharma Tech Conclave 2023

Chitkara University and DeepSynergy presents the Pharma Tech Conclave 2023. The conference will be held on 3rd Mar 2023 from 9:00 am to 5:00 pm IST at the Chitkara College of Pharmacy, Chitkara University, Chandigarh. The global pharmaceutical industry is undergoing transformational changes due to advancements in technological innovations that aim to fundamentally alter how patients…
February 22, 2023

Read more

VIEWPOINTS_Dr. Jeff Cleland_2023
VIEWPOINTS

Dr. Jeff Cleland, CEO & President at Ashvattha Therapeutics Shares his Views From First Patient Enrolled for the Treatment of AMD and DME

Shots: Jeff spoke about the first patient enrolled in a P-II study of D-4517.2 for the treatment of wet AMD and DME Jeff also talked about Ashvatta’s Hydroxyl Dendrimer Platform and how this technology is beneficial to treat AMD and DME The interview gives a profound understanding of how Ashvattha is developing hydroxyl dendrimer therapeutics…
January 3, 2023

Read more

Viewpoints_Jonathan Wall
VIEWPOINTS

Jonathan Wall, Co-founder & Interim CSO at Attralus Share Insights from its New Data Presented across its Amyloidosis Portfolio at the 2022 International Symposium on Amyloidosis

Shots: Jonathan spoke about the data presented by Attralus at the XVIII International Symposium on Amyloidosis (ISA) as both oral and poster presentations Jonathan also talked about its lead candidate, AT-01. He discussed the study design of the P-I/II clinical trial evaluating AT-01 The interview highlights Attralus vision to develop innovative medicines to improve the…
October 17, 2022

Read more

PharmShots Interview In Conversation with Biogen’s Vice President, Monica Mann, Where she Shares Insights on The Publication of Data from the NOVA Study to Treat Multiple Sclerosis
VIEWPOINTS

PharmShots Interview: In Conversation with Biogen’s Vice President, Monica Mann, Where she Shares Insights on The Publication of Data from the NOVA Study to Treat Multiple Sclerosis

Shots: Monica spoke about the data from the NOVA P-IIIb study evaluating the efficacy of its lead candidate in Multiple Sclerosis(MS) Monica also talked about the clinical trial results and formulation of the advanced product in MS The interview gives a view of Biogen’s developing molecules in the pipeline for MS Smriti: Can you share with…
July 5, 2022

Read more

Viewpoints_Joe Eazor
VIEWPOINTS

PharmaShots Interview: Clario’s Joe Eazor Shares Insight on the Clinical Trial Innovation and Evidence

In an interview with PharmaShots, Joe Eazor, CEO at Clario share his views on the ERT’s merger with Bioclinica to become Clario for clinical trial innovation and evidence ERT & Bioclinica merged to become Clario, following its Apr 2021 merger agreement & to generate the clinical evidence, empower the patients &  transform their lives by providing better evidence Clario combines Bioclinica's expertise in imaging,…
December 30, 2021

Read more

Viewpoints_James Graham
VIEWPOINTS

PharmaShots Interview: Recce Pharmaceuticals’ James Graham Shares Insight on the P-I/II Clinical Trial of RECCE 327 (R327) for Infected Burn Wounds

In an interview with PharmaShots, James Graham, CEO of Recce Pharmaceuticals shared his views on the multiple patient dosing in P-I/II clinical trial of RECCE 327 (R327) for the treatment of infected burn wounds. Shots: The multiple patients have been dosed in P-I/II trial evaluates the effectiveness & safety of RECCE 327 in 30 patients (10 will receive RECCE 327…
September 14, 2021

Read more